LifeCell, An Acelity Company

acelity.com

LifeCell is now an Acelity company! Acelity is a global market leader in advanced wound therapeutics and regenerative medicine, offering innovative solutions from the hospital to home that improve the lives of patients in more than 80 countries. Our mission is to change the practice of medicine with solutions that speed healing, create economic value and improve patients’ lives. We are the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair, and the market leader in collagen dressings. Acelity is headquartered in San Antonio, Texas, with more than 5,800 employees around the globe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

BEIGENE-NOVARTIS PD-1 DEAL; SINOVAC VACCINE; CELLTRION ANTIBODY COVID-19 DATA

Novartis | January 19, 2021

news image

Novartis plunked down up to $2.2 billion for BeiGene's China-approved PD-1 drug tislelizumab to complement its own checkpoint inhibitor. Hear what BeiGene CEO John Oyler has to say about tislelizumab's position in and outside China. Sinovac's COVID-19 vaccine reported confusing data from Brazil, raising doubt about its true efficacy. Celltron's anti-SARS-CoV-2 antibody improved patients' outcomes in a phase 2/3 trial. And more. Novartis paid $650 million upfron...

Read More

Pharmacy Market

QUVA PHARMA EXPANDS RFID CAPABILITIES FOR ITS PRE-TAGGED, READY-TO-ADMINISTER INJECTABLES

PRNewswire | June 14, 2023

news image

QuVa Pharma, Inc. announced today that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1's open, technology independent, global standards which enable interoperability and compatibility. QuVa' s portfolio of sterile, ready-to-administer syringes will be the first 503B Outsourcing facility to include the pre-tagged RFID GS1 format. "Insights from our customers and reports like ASHP's that assessed RFID utilization i...

Read More

Business Insights

EYENOVIA ANNOUNCES FDA APPROVAL OF MYDCOMBI™, THE FIRST OPHTHALMIC SPRAY FOR MYDRIASIS, WHICH ALSO LEVERAGES THE COMPANY’S PROPRIETARY

Globenewswire | May 09, 2023

news image

Eyenovia, Inc. an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first a...

Read More

Business Insights

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

news image

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More
news image

Pharma Tech

BEIGENE-NOVARTIS PD-1 DEAL; SINOVAC VACCINE; CELLTRION ANTIBODY COVID-19 DATA

Novartis | January 19, 2021

Novartis plunked down up to $2.2 billion for BeiGene's China-approved PD-1 drug tislelizumab to complement its own checkpoint inhibitor. Hear what BeiGene CEO John Oyler has to say about tislelizumab's position in and outside China. Sinovac's COVID-19 vaccine reported confusing data from Brazil, raising doubt about its true efficacy. Celltron's anti-SARS-CoV-2 antibody improved patients' outcomes in a phase 2/3 trial. And more. Novartis paid $650 million upfron...

Read More
news image

Pharmacy Market

QUVA PHARMA EXPANDS RFID CAPABILITIES FOR ITS PRE-TAGGED, READY-TO-ADMINISTER INJECTABLES

PRNewswire | June 14, 2023

QuVa Pharma, Inc. announced today that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1's open, technology independent, global standards which enable interoperability and compatibility. QuVa' s portfolio of sterile, ready-to-administer syringes will be the first 503B Outsourcing facility to include the pre-tagged RFID GS1 format. "Insights from our customers and reports like ASHP's that assessed RFID utilization i...

Read More
news image

Business Insights

EYENOVIA ANNOUNCES FDA APPROVAL OF MYDCOMBI™, THE FIRST OPHTHALMIC SPRAY FOR MYDRIASIS, WHICH ALSO LEVERAGES THE COMPANY’S PROPRIETARY

Globenewswire | May 09, 2023

Eyenovia, Inc. an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first a...

Read More
news image

Business Insights

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us